Correspondence  by unknown
LETTERS TO THE EDITOR
Heparin for Acute Myocardial Infarction:
“News” from the “Past”
We have read the report by Verheugt et al. (1) with great interest. It
suggests that early monotherapy with high dose of heparin is associated
with full coronary reperfusion in a considerable number of patients
with AMI (64% with TIMI flow 2-3) with symptoms ,2 hours.
Some features of this study present some limitations and may
deserve further investigation:
1) The cohort of patients were all eligible for primary PTCA;
2) They received a very high dose of single bolus of intravenous
heparin (300 U/Kg body weight), currently not used in standard
therapy for AMI in UCC;
3) The major rate of spontaneous lysis cannot be excluded in the
heparin group;
4) Matching study is exposed to the inevitable presence of selection
bias and, however, it has a retrospective design;
5) Sometimes the conclusion of a pilot study will not be confirmed in
a main trial.
The unexpected results urge us to feel that the role of heparin, as
an alternative chance in the pharmacological reperfusion, has been put
aside too quickly. To support this suggestion there are two “old”
reports that we have come by after the lecture of the report of
Verheugt (1):
1) The results of USIM (Urokinasi Sistemica nell’Infarto Miocardico),
an Italian randomized collaborative study (2). This study showed
the absence of a 16-day mortality difference in 2,531 patients with
AMI with symptoms ,4 hours, between the treated with only
intravenous heparin (a bolus dose of 10,000 U followed by 1,000
U/h for 48 hours) and the group treated with thrombolysis with
urokinase (a bolus dose of 1,000,000 U repeated after 60 minutes)
plus heparin infused at the same rate.
2) Our observations (3,4) about the effect of intravenous heparin on
early ST evolution, that is a simple, non invasive marker of indirect
coronary recanalization. We studied 60 patients with AMI, ran-
domized to thrombolysis (streptokinase 1,500,000 U/1 hour) and
intravenous heparin alone (infused at the same rate as USIM). and
no difference was found in the (ST between the two groups when
the patients treated ,2 hours from symptoms were analyzed.
However, the limits of the antithrombothic effects of heparin are
well known, especially the manner in which they affect the thrombus.
Heparin does not lyse clots; it indirectly reduces the thrombin activa-
tion postthrombolysis and can prevent clot reformation. Consequently,
the practical clinical relevance of these observations are probably poor.
In the aggressive reperfusion era, where at present, thrombolysis and
PTCA are at the front line for early treatment in AMI, to suppose the
performing of a large randomized trial to evaluate the role of
intravenous heparin monotherapy is no longer ethical. Moreover, in
times where saving money is mandatory, it is provocative to think that
we can rely on early bolus of heparin as another reperfusion alternative
in selected groups of patients with AMI.
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Reply
Considerations by Drs. Di Tano may be of interest and we fully agree
that only a randomized trial may answer their questions.
The main purpose of the HEAP pilot study (1) was to cover the
door-to-balloon time in a way that may induce preangioplasty reper-
fusion. We agree that the results were unexpected, but we were aware
of the previously presented USIM trial (2). However, we did not
discuss the outcome of this large randomized comparison between
urokinase and heparin, because:
1. The dose of heparin cannot be compared with the 300 U/kg used in
the HEAP pilot study; and
2. The dose of urokinase in the trial (2,000,000 U) may have been too
low to achieve full reperfusion.
Finally, it should be clear that megadose bolus heparin can never
be an alternative to thrombolysis, but only an adjunct to primary PTCA
in an attempt to increase pre-angioplasty reperfusion. We are also
aware of other agents than heparin, which might induce pre-
angioplasty reperfusion, might achieve pre-angioplasty patency (3).
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